Genomic Health Expanding Sales Force by 20 Percent; Starts Prostate Dx Studies
January 09, 2012
Genomic Health Expanding Sales Force by 20 Percent; Starts Prostate Dx Studies
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter - Genomic Health Inks PGx Alliance with OncoMed
May 2, 2012 / GenomeWeb Daily News - Reporting Another Profitable Year, Genomic Health Considers Prostate Cancer Dx Next Big Opportunity
February 8, 2012 / Pharmacogenomics Reporter - After Profitable Year, Genomic Health to Invest in New Products, Overseas Market, Next-Gen Sequencing
February 16, 2011 / Pharmacogenomics Reporter - Genomic Health Updates Investors on Timeline for DCIS, Colon Cancer, Prostate Cancer Tests
September 29, 2010 / Pharmacogenomics Reporter